Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Most of the identified aldose reductase inhibitors possess u
2024-05-06

Most of the identified aldose reductase inhibitors possess undesirable effects like poor pharmacokinetic properties, hypersensitivity and Steven-Johnson Syndrome [1]. However, the main side effect is the lack of selectivity relative to aldehyde reductase (ALR1, EC 1.1.1.2). ALR1 plays the important
-
Chlorpropamide Recent studies demonstrated that AHR
2024-05-06

Recent studies demonstrated that AHR has an important role in the interplay between cancer metabolism and tumor-specific immunity. Tryptophan catabolism is increasingly recognized as a metabolic pathway that promotes tumorigenesis through its role in immune suppression [75]. The rate-limiting enzyme
-
br Acknowledgements Dr Paul J Gasser is
2024-05-06

Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N
-
br Experimental procedure br Introduction Migraine
2024-05-06

Experimental procedure Introduction Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating headaches of moderate to severe intensity, associated with nausea, photophobia and/or phonophobia, lasting from 4 to 72 h (Headache Classification Committee of
-
br Concluding Remarks The effects
2024-05-06

Concluding Remarks The effects of point mutations of the four ARs on ligand binding affinities, functional potencies, and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allow
-
In the past years the role of
2024-05-06

In the past 10 years, the role of the CD73-adenosinergic pathway in suppression of anti-tumor immunity has increasingly been recognized [13], [14]. In this review, we discuss the latest findings dealing with the regulation of anti-tumor immunity by CD73 and adenosine. We also discuss ongoing clinica
-
PL for actin in vitro
2024-05-03

PL for Piceatannol in vitro showed that its profiles, including particular peak and intensity, could determine the length and thickness of an actin filament. Furthermore, we investigated if the PL intensity peak at approximately 340 nm can also be originated from another cytoskeleton filament, such
-
REM sleep is proposed to create an environment to
2024-05-03

REM sleep is proposed to create an environment to facilitate plasticity processes that create a generalized downregulation of synaptic strength (Grosmark et al., 2012; Tononi and Cirelli, 2014), while synapses are upregulated specifically by the reactivation of neuronal firing sequences experienced
-
The AAP s policy statement on
2024-05-03

The AAP’s policy statement on childhood adversities is a call to the pediatric IL-4, murine recombinant to apply the knowledge toward developmental screening in clinical practice. It is a movement to increase education around childhood adversity as a public health crisis and to build trauma-informed
-
br Conclusions The present protocol
2024-05-03

Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A
-
The incremental reduction albeit not statistically significa
2024-05-03

The incremental reduction, albeit not statistically significant, in collagen I with LCZ696 compared to perindopril treated animals, may therefore be related to a more compliant ventricle in LCZ696-treated animals. This is not so surprising given the incremental anti-fibrotic effect of the active met
-
br MHCI peptide editing N terminal extensions
2024-05-02

MHCI peptide editing, N-terminal extensions and the peptide loading complex Conventionally, peptide-MHCI binding is thought to require both amino- and carboxyl-termini for stable interaction (Madden, 1995; Bouvier and Wiley, 1994). Peptides with longer than optimal length (10–13 residues) have be
-
Exposure to B a P is an epidemiologically proven
2024-05-02

Exposure to B[a]P is an epidemiologically proven cause of lung cancer (Hecht, 2003; Rojas et al., 2004; Alexandrov et al., 2010), and the formation of B[a]PDE-N2-dG adducts is considered to be the critical event in lung tumorigenesis by B[a]P. On the other hand, there is evidence suggesting that the
-
A high throughput small molecule ACK biochemical inhibition
2024-04-30

A high-throughput small molecule ACK1 biochemical inhibition screen was performed in-house and led to the identification of 1μM inhibitor furanopyrimidine (). Further binding studies found protease inhibitors to be both ATP-competitive and reversible. Early structure-activity relationship (SAR) w
-
Finasteride has been shown to be a mechanism
2024-04-30

Finasteride has been shown to be a mechanism-based inhibitor of 5AR-2 [9]. Finasteride acts as an alternate substrate for 5AR-2 and is initially bound in an extremely stable enzyme-bound NADP-dihydrofinasteride adduct which is ultimately processed to dihydrofinasteride. The NADP-dihydrofinasteride a
16674 records 175/1112 page Previous Next First page 上5页 171172173174175 下5页 Last page